Open-label, Multicenter, Phase II Study of RC48-ADC, a HER2-Targeting Antibody–Drug Conjugate, in Patients with Locally Advanced or Metastatic Urothelial Carcinoma
Top Cited Papers
- 1 January 2021
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 27 (1), 43-51
- https://doi.org/10.1158/1078-0432.ccr-20-2488
Abstract
Purpose: To evaluate the efficacy and safety of RC48-ADC, a novel humanized anti-HER2 antibody conjugated with monomethyl auristatin E (MMAE), in patients with HER2-positive locally advanced or metastatic urothelial carcinoma (mUC) refractory to standard therapies. Patients and methods: This was a phase 2, open-label, multicenter, single-arm study of patients with HER2-positive (immunohistochemical status 3+ or 2+) locally advanced or metastatic UC who previously failed with at least one line systemic chemotherapy. The primary endpoint was the objective response rate (ORR) assessed by a blinded independent review committee (BIRC). The secondary endpoint included progression-free survival (PFS), disease control rate, duration of response, overall survival (OS), and safety. Results: Forty-three patients were enrolled. The median follow-up was 20.3 months. The overall confirmed ORR as assessed by the BIRC was 51.2% (95% CI: 35.5%, 66.7%). Similar responses were observed in prespecified subgroups, such as those with liver metastasis and those previously treated with anti-PD-1/L1 therapies. The median PFS and OS were 6.9 months (95% CI: 5.6, 8.9) and 13.9 months (95% CI: 9.1, NE), respectively. The most common treatment-related adverse events (TRAEs) were hypoaesthesia (60.5%), alopecia (55.8%), and leukopenia (55.8%). Twenty-five (58%) patients experienced Grade 3 TRAEs, including hypoaesthesia (23.3%) and neutropenia (14.0%). No Grade 4 or Grade 5 TRAEs occurred. Conclusions: RC48-ADC demonstrated a promising efficacy with a manageable safety profile in HER2-positive locally advanced or metastatic UC patients who had failed at least one line of systemic chemotherapy.Keywords
Other Versions
Funding Information
- Natural Science Foundation of China (81672696)
- Beijing Municipal Administration of Hospitals (DFL20181101)
- Beijing Municipal Science and Technology Commission (Z161100000516062)
This publication has 26 references indexed in Scilit:
- Targeting HER2 with T-DM1, an Antibody Cytotoxic Drug Conjugate, is Effective in HER2 Over Expressing Bladder CancerJournal of Urology, 2015
- Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline UpdateJournal of Clinical Oncology, 2013
- Predictive factors for worse pathological outcomes of upper tract urothelial carcinoma: experience from a nationwide high‐volume centre in ChinaBJU International, 2013
- Randomized Phase III Study Comparing Paclitaxel/Cisplatin/ Gemcitabine and Gemcitabine/Cisplatin in Patients With Locally Advanced or Metastatic Urothelial Cancer Without Prior Systemic Therapy: EORTC Intergroup Study 30987Journal of Clinical Oncology, 2012
- Her2 Amplification is Significantly More Frequent in Lymph Node Metastases From Urothelial Bladder Cancer Than in the Primary TumoursEuropean Urology, 2011
- Assessing HER2 gene amplification as a potential target for therapy in invasive urothelial bladder cancer with a standardized methodology: results in 1005 patientsAnnals of Oncology, 2010
- Phase III Trial of Vinflunine Plus Best Supportive Care Compared With Best Supportive Care Alone After a Platinum-Containing Regimen in Patients With Advanced Transitional Cell Carcinoma of the Urothelial TractJournal of Clinical Oncology, 2009
- A single‐arm, multicenter, open‐label phase 2 study of lapatinib as the second‐line treatment of patients with locally advanced or metastatic transitional cell carcinomaCancer, 2009
- Trastuzumab, Paclitaxel, Carboplatin, and Gemcitabine in Advanced Human Epidermal Growth Factor Receptor-2/neu–Positive Urothelial Carcinoma: Results of a Multicenter Phase II National Cancer Institute TrialJournal of Clinical Oncology, 2007
- Long-Term Survival Results of a Randomized Trial Comparing Gemcitabine Plus Cisplatin, With Methotrexate, Vinblastine, Doxorubicin, Plus Cisplatin in Patients With Bladder CancerJournal of Clinical Oncology, 2005